{"id":"W4376286734","doi":"10.1016/j.eururo.2023.04.031","title":"Re: Darolutamide plus Androgen-deprivation Therapy and Docetaxel in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial","year":2023,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Hazard ratio; Prostate cancer; Docetaxel; Prednisone; Abiraterone acetate; Internal medicine; Oncology; Proportional hazards model; Confidence interval; Androgen deprivation therapy; Enzalutamide; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002925228,0.0006213493,0.0014815,0.0002945376,0.0009543715,0.001497522,0.0009641714,0.009316647,0.007705434],"category_scores_gemma":[0.00765863,0.0003532415,0.0008284627,0.0004335321,0.0006041998,0.001209313,0.0004020214,0.009365153,0.004706902],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00251149,"about_ca_system_score_gemma":0.002115306,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002826996,"about_ca_topic_score_gemma":0.009728489,"domain_scores_codex":[0.9986715,0.0006541816,0.0001302533,0.0001352112,0.0002403512,0.0001684638],"domain_scores_gemma":[0.9967069,0.001837563,0.000314671,0.00008890631,0.000284019,0.0007680458],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01011382,0.0002816654,0.002280216,0.0002251506,0.0001388902,0.001093678,0.00006061308,0.0002717122,0.0007384262,0.002024574,0.9254583,0.05731295],"study_design_scores_gemma":[0.03923732,0.003024059,0.0151998,0.0009787771,0.0006770318,0.002814344,0.0002851578,0.0034691,0.00203689,0.01465495,0.9174707,0.0001519096],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.01328254,0.009470842,0.0002631607,0.9112287,0.03716381,0.0002215761,0.00223817,0.0001334447,0.02599784],"genre_scores_gemma":[0.06435757,0.004410504,0.0006095477,0.8325428,0.05332578,0.0004951303,0.001202822,0.0001134704,0.04294232],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.009316647,"threshold_uncertainty_score":0.02577722,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03953950541478287,"score_gpt":0.3162875686684111,"score_spread":0.2767480632536283,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}